Resolving Diabetic Ketoacidosis
Core Resolution Parameters
- The American Diabetes Association recommends DKA resolution requires a glucose <200 mg/dL, serum bicarbonate ≥18 mEq/L, and venous pH >7.3 1, 2
- Glucose level <200 mg/dL is a key parameter for resolving DKA, as recommended by the American Diabetes Association 1, 2
- Serum bicarbonate ≥18 mEq/L is a critical parameter for resolving DKA, as recommended by the American Diabetes Association 1, 2
- Venous pH >7.3 is a necessary parameter for resolving DKA, as recommended by the American Diabetes Association 1, 2
- Anion gap ≤12 mEq/L is a relevant parameter for resolving DKA, as recommended by the American Diabetes Association 3
Monitoring During DKA Treatment
- Blood should be drawn every 2-4 hours for determination of serum electrolytes, glucose, blood urea nitrogen, creatinine, osmolality, and venous pH, as recommended by the American Diabetes Association 2, 4
- Venous pH (typically 0.03 units lower than arterial pH) and anion gap can be followed to monitor resolution of acidosis, with a strength of evidence level of high 2
Ketone Monitoring Considerations
- Ketonemia typically takes longer to clear than hyperglycemia, with a strength of evidence level of moderate 4, 5
- Direct measurement of β-hydroxybutyrate (β-OHB) in blood is the preferred method for monitoring DKA, as recommended by the American Diabetes Association 2, 5
- The nitroprusside method only measures acetoacetic acid and acetone, not β-OHB, and should not be used as indicators of treatment response, with a strength of evidence level of high 2, 5
Post-Resolution Management
- Once DKA is resolved, if patient is NPO, continue intravenous insulin and fluid replacement, and supplement with subcutaneous regular insulin as needed every 4 hours, as recommended by the American Diabetes Association 1, 2
- For adult patients, give 5-unit increments for every 50 mg/dL increase in blood glucose above 150 mg/dL (up to 20 units for blood glucose of 300 mg/dL), with a strength of evidence level of moderate 1, 2
- When patient is able to eat, start a multiple-dose schedule using a combination of short/rapid-acting and intermediate/long-acting insulin, as recommended by the American Diabetes Association 1, 2
- Continue intravenous insulin infusion for 1-2 hours after starting subcutaneous insulin to ensure adequate plasma insulin levels, with a strength of evidence level of high 1, 5
Management of Diabetic Ketoacidosis with Variable Glucose Levels
Assessment and Monitoring
- The American Diabetes Association recommends evaluating for possible causes of persistent or worsening ketoacidosis despite insulin therapy, including infection, inadequate insulin dosing, or interruption of insulin therapy 6
Insulin Management
- The American Diabetes Association recommends continuing intravenous insulin infusion despite variable glucose levels, and not interrupting or discontinuing intravenous insulin therapy when glucose levels fall, as this is a common cause of persistent or worsening ketoacidosis 7
- The American Diabetes Association recommends adding dextrose to the hydrating solution while continuing insulin infusion when glucose falls below 200-250 mg/dL 8, 9
Glucose Management Algorithm
- The American Diabetes Association recommends targeting glucose between 150-200 mg/dL until DKA resolution (pH >7.3, bicarbonate ≥18 mEq/L, and anion gap ≤12 mEq/L) 6, 9
Electrolyte Management
- The American Diabetes Association recommends monitoring potassium levels closely, as insulin administration can cause hypokalemia, and ensuring adequate potassium replacement to maintain serum K+ between 4-5 mmol/L 6, 7
Common Pitfalls to Avoid
- The American Diabetes Association warns that overzealous treatment with insulin without glucose supplementation can lead to hypoglycemia, and interruption of insulin infusion is a common cause of persistent or worsening ketoacidosis 7
Serum Glucose Threshold for D5 Administration in DKA Management
Rationale for D5 Administration in DKA
- The American Diabetes Association recommends that when managing diabetic ketoacidosis (DKA) with insulin, dextrose 5% (D5) should be administered when serum glucose reaches 250 mg/dL to prevent hypoglycemia while continuing insulin therapy to resolve ketosis 10, 11
- Ketonemia typically takes longer to clear than hyperglycemia, necessitating continued insulin therapy even after glucose normalizes 10
Fluid Management Protocol
- Initial fluid resuscitation should use 0.9% NaCl or other crystalloid at a clinically appropriate rate 12, 13
- When serum glucose reaches 250 mg/dL, change fluid to 5% dextrose with 0.45-0.75% NaCl 10, 11
- Continue potassium supplementation in the D5 solution as needed to maintain serum potassium levels between 4-5 mmol/L 10, 11
Insulin Management During DKA Resolution
Monitoring During Treatment
- Check electrolytes, renal function, venous pH, osmolality, and glucose every 2-4 hours until stable 12, 13
Common Pitfalls to Avoid
- Failure to add dextrose when glucose falls below 250 mg/dL while continuing insulin therapy 10, 11
- Inadequate monitoring of electrolytes, particularly potassium, during treatment 10
Special Considerations
- In euglycemic DKA (glucose <250 mg/dL with ketoacidosis), D5 should be started alongside 0.9% NaCl at the beginning of insulin treatment 12
- For pediatric patients, the threshold for adding dextrose may be similar, but fluid rates should be adjusted appropriately for weight 10, 11
DKA Resolution and Management
Monitoring and Resolution Criteria
- Venous pH is sufficient for monitoring acidosis resolution, and can be used in place of repeat arterial blood gases, as it adequately tracks acidosis resolution, with a typical difference of 0.03 units lower than arterial pH 14
- The anion gap provides additional confirmation of ketoacid clearance and should be followed in parallel with pH, as it indicates clearance of ketoacids from the circulation 14
Insulin Therapy After Resolution
- The American Diabetes Association recommends transitioning to subcutaneous insulin using a multiple-dose regimen combining short/rapid-acting and intermediate/long-acting insulin after DKA resolution, as outlined in the Diabetes Care guidelines 14
Management of Diabetic Ketoacidosis
Insulin Regimens
- The American Diabetes Association recommends starting a multiple-dose subcutaneous insulin regimen combining short/rapid-acting and intermediate/long-acting insulin once DKA is resolved and the patient can eat 15
- For patients on enteral feedings who require insulin, bolus feedings should be covered with regular or rapid-acting insulin subcutaneously before each feeding, starting with 1 unit per 10-15 g carbohydrate, as recommended by the American Diabetes Association 15, 16
- Continuous feedings should be covered with NPH/detemir every 12 hours or glargine/degludec daily for basal coverage, plus regular insulin every 6 hours or rapid-acting every 4 hours for nutritional needs, according to the American Diabetes Association 15, 16
- Correctional insulin should be added subcutaneously every 4-6 hours as needed for hyperglycemia, as suggested by the American Diabetes Association 15, 16
Basal Insulin Coverage
- The American Diabetes Association suggests ensuring basal insulin coverage continues, particularly critical for type 1 diabetes patients even when not eating 16
Management of Diabetic Ketoacidosis
Initiation and Adjustment of Intravenous Fluids and Insulin
- The American Diabetes Association recommends adding dextrose 5% to the intravenous fluids when serum glucose falls to 250 mg/dL, while continuing insulin infusion to resolve ketosis 17
- The goal is to maintain serum glucose between 150-200 mg/dL until complete resolution of diabetic ketoacidosis 17
Monitoring and Laboratory Tests
- The American Diabetes Association recommends checking electrolytes, renal function, venous pH, osmolality, and glucose every 2-4 hours until they are stable 17
- Potassium serum levels should be maintained between 4-5 mmol/L by adding potassium to each liter of intravenous fluid 17
Special Considerations
- In cases of euglycemic diabetic ketoacidosis (glucose <250 mg/dL at the start of treatment), dextrose 5% should be initiated along with 0.9% saline solution from the beginning of insulin treatment 17